Alkem Laboratories informs about press release

25 Sep 2023 Evaluate

Alkem Laboratories has informed that the Company and Biosergen AB (‘Biosergen’), have entered into a co-development and license agreement for the development and commercialization of Biosergen’s novel polyene macrolide antifungal product BSG005 for the treatment of severe invasive fungal disease. A press release in this regard is enclosed.

The above information is a part of company’s filings submitted to BSE.

Alkem Laboratories Share Price

5765.40 107.60 (1.90%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1371.55
Zydus Lifesciences 884.85
Lupin 2165.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×